Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience
AS Folkes, M Feng, JM Zain, F Abdulla… - Current opinion in …, 2018 - journals.lww.com
AS Folkes, M Feng, JM Zain, F Abdulla, ST Rosen, C Querfeld
Current opinion in oncology, 2018•journals.lww.comIn the CTCL tumor microenvironment, increased immune checkpoint inhibition expression
via CD47 bound to SIRPα correlates with a more advanced disease state. Continued
success in treating these patients requires further studies on CD47 antagonists, specifically
when combined with other antibodies.
via CD47 bound to SIRPα correlates with a more advanced disease state. Continued
success in treating these patients requires further studies on CD47 antagonists, specifically
when combined with other antibodies.
Summary
In the CTCL tumor microenvironment, increased immune checkpoint inhibition expression via CD47 bound to SIRPα correlates with a more advanced disease state. Continued success in treating these patients requires further studies on CD47 antagonists, specifically when combined with other antibodies.
Lippincott Williams & Wilkins